Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Dandurand, Ann; Ouyang, John; Czerwiec, Frank S; Blais, Jaime D (2018). Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, Dialysis, Transplantation, 33(3):477-489.

Cornec-Le Gall, Emilie; Blais, Jaime D; Irazabal, Maria V; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ron D; Chapman, Arlene B; Czerwiec, Frank S; Ouyang, John; Heyer, Christina M; Senum, Sarah R; Le Meur, Yannick; Torres, Vicente E; Harris, Peter C (2018). Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, Dialysis, Transplantation, 33(4):645-652.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Koch, Gary; Ouyang, John; McQuade, Robert D; Blais, Jaime D; Czerwiec, Frank S; Sergeyeva, Olga (2017). Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 377(20):1930-1942.

Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Higashihara, Eiji; Perrone, Ronald D; Torres, Vicente E; Blais, Jaime D; Zhou, Wen; Ouyang, John; Czerwiec, Frank S (2017). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology (JASN), 28(5):1592-1602.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Dandurand, Ann; Ouyang, John; Czerwiec, Frank S; Blais, Jaime D (2017). Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, Dialysis, Transplantation, 32(7):1262.

Torres, Vicente E; Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Perrone, Ronald D; Ouyang, John; Blais, Jaime D; Czerwiec, Frank S; Sergeyeva, Olga (2017). Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 45(3):257-266.

Devuyst, Olivier; Chapman, Arlene B; Shoaf, Susan E; Czerwiec, Frank S; Blais, Jaime D (2017). Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney International Reports, 2(6):1132-1140.

Casteleijn, Niek F; Blais, Jaime D; Chapman, Arlene B; Czerwiec, Frank S; Devuyst, Olivier; Higashihara, Eiji; Leliveld, Anna M; Ouyang, John; Perrone, Ronald D; Torres, Vicente E; Gansevoort, Ron T (2017). Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American Journal of Kidney Diseases, 69(2):210-219.

This list was generated on Sat Feb 23 21:30:24 2019 CET.